 Stephen Waldo
Concepts (407)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Percutaneous Coronary Intervention | 75 | 2025 | 467 | 19.290 |
Why?
| | Coronary Artery Disease | 45 | 2025 | 680 | 11.130 |
Why?
| | United States Department of Veterans Affairs | 30 | 2025 | 628 | 5.190 |
Why?
| | Coronary Angiography | 31 | 2025 | 306 | 3.750 |
Why?
| | Peripheral Arterial Disease | 25 | 2020 | 458 | 3.430 |
Why?
| | Myocardial Infarction | 28 | 2024 | 1021 | 3.420 |
Why?
| | Endovascular Procedures | 18 | 2020 | 301 | 3.310 |
Why?
| | Treatment Outcome | 90 | 2025 | 10221 | 2.850 |
Why?
| | Femoral Artery | 13 | 2022 | 174 | 2.850 |
Why?
| | Veterans | 16 | 2024 | 1383 | 2.740 |
Why?
| | Acute Coronary Syndrome | 7 | 2024 | 267 | 2.630 |
Why?
| | Vascular Calcification | 9 | 2022 | 107 | 2.460 |
Why?
| | Veterans Health | 7 | 2025 | 179 | 2.380 |
Why?
| | Stents | 21 | 2019 | 504 | 2.340 |
Why?
| | ST Elevation Myocardial Infarction | 6 | 2022 | 52 | 2.230 |
Why?
| | Popliteal Artery | 11 | 2020 | 58 | 2.200 |
Why?
| | Registries | 28 | 2023 | 1896 | 2.110 |
Why?
| | Atherectomy | 11 | 2022 | 37 | 2.020 |
Why?
| | Risk Factors | 68 | 2025 | 9787 | 2.020 |
Why?
| | Ischemia | 11 | 2020 | 405 | 1.840 |
Why?
| | Coronary Artery Bypass | 7 | 2023 | 224 | 1.840 |
Why?
| | Time Factors | 51 | 2025 | 6545 | 1.800 |
Why?
| | Atherectomy, Coronary | 5 | 2022 | 10 | 1.770 |
Why?
| | United States | 58 | 2025 | 13906 | 1.750 |
Why?
| | Aged | 84 | 2025 | 22101 | 1.730 |
Why?
| | Risk Assessment | 28 | 2025 | 3260 | 1.730 |
Why?
| | Time-to-Treatment | 5 | 2024 | 179 | 1.640 |
Why?
| | Lower Extremity | 4 | 2018 | 407 | 1.630 |
Why?
| | Radial Artery | 7 | 2022 | 69 | 1.610 |
Why?
| | Angioplasty, Balloon, Coronary | 6 | 2017 | 140 | 1.590 |
Why?
| | Platelet Aggregation Inhibitors | 7 | 2023 | 443 | 1.500 |
Why?
| | Middle Aged | 79 | 2025 | 31165 | 1.460 |
Why?
| | Hospitals, Veterans | 4 | 2025 | 242 | 1.400 |
Why?
| | Cardiovascular Agents | 7 | 2023 | 157 | 1.380 |
Why?
| | Humans | 154 | 2025 | 129687 | 1.380 |
Why?
| | Non-ST Elevated Myocardial Infarction | 3 | 2020 | 19 | 1.350 |
Why?
| | Hospital Mortality | 13 | 2025 | 851 | 1.320 |
Why?
| | Biological Products | 2 | 2023 | 207 | 1.310 |
Why?
| | Coronary Vessels | 7 | 2025 | 239 | 1.240 |
Why?
| | Coronary Restenosis | 4 | 2017 | 21 | 1.230 |
Why?
| | Male | 97 | 2025 | 63691 | 1.220 |
Why?
| | Angioplasty, Balloon | 9 | 2020 | 92 | 1.200 |
Why?
| | Myocardial Revascularization | 3 | 2019 | 72 | 1.110 |
Why?
| | Female | 91 | 2025 | 68751 | 1.100 |
Why?
| | Access to Information | 2 | 2019 | 47 | 1.090 |
Why?
| | Catheterization, Peripheral | 2 | 2019 | 104 | 1.080 |
Why?
| | Retrospective Studies | 50 | 2025 | 14525 | 1.040 |
Why?
| | Surgical Procedures, Operative | 3 | 2025 | 243 | 1.000 |
Why?
| | Myocardial Ischemia | 4 | 2020 | 259 | 0.970 |
Why?
| | Angina, Stable | 3 | 2022 | 17 | 0.950 |
Why?
| | Patient Readmission | 8 | 2024 | 668 | 0.920 |
Why?
| | Eligibility Determination | 1 | 2025 | 63 | 0.920 |
Why?
| | Quality Improvement | 5 | 2025 | 1108 | 0.910 |
Why?
| | Coated Materials, Biocompatible | 6 | 2020 | 59 | 0.900 |
Why?
| | Cardiology | 4 | 2022 | 266 | 0.890 |
Why?
| | Myocardial Reperfusion | 2 | 2013 | 50 | 0.850 |
Why?
| | Cardiac Catheterization | 5 | 2025 | 520 | 0.840 |
Why?
| | Quality of Health Care | 2 | 2019 | 609 | 0.840 |
Why?
| | Stroke Volume | 3 | 2021 | 592 | 0.820 |
Why?
| | Vascular Patency | 14 | 2020 | 102 | 0.810 |
Why?
| | Ventricular Function, Left | 3 | 2021 | 528 | 0.800 |
Why?
| | Chickens | 1 | 2023 | 188 | 0.790 |
Why?
| | Heart Arrest | 3 | 2017 | 320 | 0.790 |
Why?
| | Healthcare Disparities | 3 | 2024 | 580 | 0.780 |
Why?
| | Elective Surgical Procedures | 2 | 2020 | 165 | 0.770 |
Why?
| | Psoriasis | 1 | 2023 | 87 | 0.770 |
Why?
| | Vascular Access Devices | 5 | 2020 | 26 | 0.770 |
Why?
| | Coronary Thrombosis | 4 | 2015 | 24 | 0.770 |
Why?
| | California | 18 | 2019 | 400 | 0.750 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2023 | 430 | 0.740 |
Why?
| | Practice Patterns, Physicians' | 7 | 2025 | 1271 | 0.740 |
Why?
| | Anemia | 2 | 2022 | 161 | 0.720 |
Why?
| | Patient Selection | 1 | 2025 | 660 | 0.720 |
Why?
| | Coronary Occlusion | 2 | 2023 | 18 | 0.710 |
Why?
| | Heart Failure, Systolic | 1 | 2021 | 25 | 0.710 |
Why?
| | Aged, 80 and over | 21 | 2021 | 7064 | 0.700 |
Why?
| | Hemorrhage | 5 | 2022 | 679 | 0.690 |
Why?
| | Hospitals, Community | 1 | 2020 | 48 | 0.670 |
Why?
| | Drug-Eluting Stents | 6 | 2017 | 74 | 0.670 |
Why?
| | Paclitaxel | 2 | 2019 | 217 | 0.650 |
Why?
| | Assisted Circulation | 1 | 2019 | 26 | 0.650 |
Why?
| | Hemostatic Techniques | 1 | 2020 | 45 | 0.640 |
Why?
| | Quality Indicators, Health Care | 4 | 2025 | 298 | 0.630 |
Why?
| | Databases, Factual | 11 | 2025 | 1269 | 0.620 |
Why?
| | Cardiac Surgical Procedures | 2 | 2022 | 506 | 0.620 |
Why?
| | Embolic Protection Devices | 1 | 2019 | 12 | 0.620 |
Why?
| | Postoperative Hemorrhage | 1 | 2020 | 87 | 0.620 |
Why?
| | Intra-Aortic Balloon Pumping | 1 | 2019 | 17 | 0.620 |
Why?
| | Saphenous Vein | 1 | 2019 | 32 | 0.620 |
Why?
| | Graft Occlusion, Vascular | 1 | 2019 | 41 | 0.610 |
Why?
| | Fibrinolytic Agents | 2 | 2018 | 262 | 0.600 |
Why?
| | Electrocardiography | 4 | 2015 | 611 | 0.600 |
Why?
| | Arterial Occlusive Diseases | 1 | 2018 | 80 | 0.580 |
Why?
| | Arm | 1 | 2018 | 107 | 0.560 |
Why?
| | Odds Ratio | 8 | 2021 | 1021 | 0.560 |
Why?
| | Peripheral Vascular Diseases | 1 | 2018 | 102 | 0.560 |
Why?
| | Propensity Score | 6 | 2024 | 265 | 0.560 |
Why?
| | Thromboembolism | 1 | 2018 | 112 | 0.550 |
Why?
| | Kaplan-Meier Estimate | 12 | 2020 | 851 | 0.550 |
Why?
| | Cerebrovascular Disorders | 1 | 2018 | 90 | 0.550 |
Why?
| | Limb Salvage | 7 | 2019 | 57 | 0.540 |
Why?
| | Postoperative Complications | 4 | 2025 | 2470 | 0.540 |
Why?
| | Embolism | 1 | 2017 | 40 | 0.530 |
Why?
| | Contrast Media | 4 | 2025 | 393 | 0.530 |
Why?
| | Renal Artery Obstruction | 1 | 2017 | 29 | 0.530 |
Why?
| | Renal Artery | 1 | 2017 | 34 | 0.530 |
Why?
| | Heart Failure | 6 | 2023 | 2147 | 0.530 |
Why?
| | Aspirin | 2 | 2019 | 380 | 0.530 |
Why?
| | Research Report | 1 | 2017 | 76 | 0.520 |
Why?
| | Hospitals | 4 | 2023 | 646 | 0.520 |
Why?
| | Catheterization | 3 | 2021 | 174 | 0.500 |
Why?
| | Hospitalization | 4 | 2025 | 2075 | 0.480 |
Why?
| | Coronary Stenosis | 5 | 2020 | 39 | 0.480 |
Why?
| | Iliac Artery | 4 | 2019 | 55 | 0.470 |
Why?
| | Hypertension, Pulmonary | 5 | 2025 | 1894 | 0.450 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 209 | 0.450 |
Why?
| | Disclosure | 1 | 2015 | 110 | 0.440 |
Why?
| | Cohort Studies | 10 | 2023 | 5434 | 0.430 |
Why?
| | Thrombectomy | 2 | 2014 | 58 | 0.430 |
Why?
| | Cell Separation | 1 | 2015 | 315 | 0.430 |
Why?
| | Depressive Disorder | 1 | 2017 | 367 | 0.420 |
Why?
| | Atherosclerosis | 3 | 2019 | 402 | 0.420 |
Why?
| | Vascular Surgical Procedures | 1 | 2016 | 295 | 0.410 |
Why?
| | Cardiologists | 2 | 2025 | 46 | 0.400 |
Why?
| | Predictive Value of Tests | 9 | 2025 | 1950 | 0.400 |
Why?
| | Disease Management | 1 | 2017 | 588 | 0.400 |
Why?
| | Acute Kidney Injury | 5 | 2025 | 789 | 0.400 |
Why?
| | Survival Rate | 6 | 2021 | 1872 | 0.400 |
Why?
| | Peer Review | 2 | 2025 | 49 | 0.380 |
Why?
| | HIV | 1 | 2013 | 227 | 0.380 |
Why?
| | Attitude of Health Personnel | 1 | 2019 | 1103 | 0.380 |
Why?
| | Logistic Models | 6 | 2017 | 1988 | 0.380 |
Why?
| | Intermittent Claudication | 3 | 2017 | 118 | 0.370 |
Why?
| | Hypothermia | 1 | 2011 | 34 | 0.360 |
Why?
| | Out-of-Hospital Cardiac Arrest | 2 | 2024 | 70 | 0.360 |
Why?
| | Incidence | 7 | 2021 | 2644 | 0.360 |
Why?
| | Cause of Death | 3 | 2023 | 395 | 0.350 |
Why?
| | Mentoring | 2 | 2023 | 132 | 0.320 |
Why?
| | Proportional Hazards Models | 9 | 2023 | 1199 | 0.320 |
Why?
| | Endothelial Cells | 1 | 2015 | 749 | 0.320 |
Why?
| | Mortality | 3 | 2020 | 308 | 0.320 |
Why?
| | Constriction, Pathologic | 9 | 2020 | 234 | 0.310 |
Why?
| | Peptide Fragments | 2 | 2015 | 695 | 0.310 |
Why?
| | Chi-Square Distribution | 4 | 2018 | 515 | 0.310 |
Why?
| | Transcatheter Aortic Valve Replacement | 2 | 2021 | 121 | 0.300 |
Why?
| | Severity of Illness Index | 7 | 2022 | 2739 | 0.300 |
Why?
| | Punctures | 2 | 2019 | 40 | 0.300 |
Why?
| | Angiography | 6 | 2020 | 196 | 0.290 |
Why?
| | Laser Therapy | 2 | 2019 | 129 | 0.290 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2008 | 99 | 0.280 |
Why?
| | Carotid Stenosis | 2 | 2018 | 84 | 0.270 |
Why?
| | Emergency Medical Services | 1 | 2013 | 522 | 0.270 |
Why?
| | Myocardial Perfusion Imaging | 2 | 2019 | 36 | 0.270 |
Why?
| | Recurrence | 9 | 2019 | 1012 | 0.260 |
Why?
| | HIV Infections | 3 | 2023 | 2730 | 0.260 |
Why?
| | Ultrasonography, Interventional | 2 | 2025 | 128 | 0.250 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2021 | 385 | 0.250 |
Why?
| | Multivariate Analysis | 5 | 2017 | 1500 | 0.250 |
Why?
| | Macrophages | 3 | 2008 | 1489 | 0.240 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2023 | 567 | 0.240 |
Why?
| | Acute Disease | 3 | 2017 | 980 | 0.240 |
Why?
| | Patient Discharge | 3 | 2022 | 856 | 0.240 |
Why?
| | Purinergic P2Y Receptor Antagonists | 2 | 2023 | 66 | 0.240 |
Why?
| | Tomography, Optical Coherence | 2 | 2025 | 186 | 0.240 |
Why?
| | Peer Review, Health Care | 1 | 2025 | 4 | 0.240 |
Why?
| | Chest Pain | 3 | 2022 | 88 | 0.230 |
Why?
| | Chemokine CXCL12 | 1 | 2025 | 79 | 0.230 |
Why?
| | Follow-Up Studies | 6 | 2021 | 4892 | 0.230 |
Why?
| | Comorbidity | 5 | 2020 | 1551 | 0.220 |
Why?
| | Pancreas | 2 | 2004 | 305 | 0.220 |
Why?
| | Stroke | 6 | 2022 | 1072 | 0.220 |
Why?
| | Sex Factors | 4 | 2024 | 1973 | 0.220 |
Why?
| | Prosthesis Failure | 2 | 2016 | 114 | 0.220 |
Why?
| | Hypothermia, Induced | 1 | 2024 | 76 | 0.210 |
Why?
| | Hypertension, Portal | 1 | 2024 | 61 | 0.210 |
Why?
| | Cross-Sectional Studies | 6 | 2022 | 5083 | 0.210 |
Why?
| | Coronary Circulation | 2 | 2014 | 138 | 0.210 |
Why?
| | Fractional Flow Reserve, Myocardial | 2 | 2020 | 8 | 0.200 |
Why?
| | Biological Therapy | 1 | 2023 | 28 | 0.200 |
Why?
| | Prognosis | 6 | 2021 | 3772 | 0.200 |
Why?
| | New York | 3 | 2017 | 128 | 0.200 |
Why?
| | Work Engagement | 1 | 2022 | 10 | 0.190 |
Why?
| | Clinical Decision-Making | 1 | 2025 | 302 | 0.190 |
Why?
| | Chronic Disease | 5 | 2023 | 1723 | 0.190 |
Why?
| | Critical Illness | 8 | 2020 | 759 | 0.190 |
Why?
| | Leukocytes | 1 | 2003 | 306 | 0.190 |
Why?
| | Technology Transfer | 1 | 2021 | 10 | 0.190 |
Why?
| | Hemodynamics | 4 | 2024 | 1091 | 0.180 |
Why?
| | Social Class | 1 | 2023 | 259 | 0.180 |
Why?
| | Anticoagulants | 2 | 2016 | 637 | 0.170 |
Why?
| | Shock, Cardiogenic | 2 | 2021 | 60 | 0.170 |
Why?
| | Angina Pectoris | 1 | 2020 | 67 | 0.170 |
Why?
| | Aftercare | 1 | 2022 | 206 | 0.170 |
Why?
| | Mandatory Reporting | 2 | 2017 | 45 | 0.170 |
Why?
| | Patient Care Team | 1 | 2025 | 601 | 0.170 |
Why?
| | Thrombocytopenia | 1 | 2022 | 189 | 0.170 |
Why?
| | Exercise Test | 2 | 2022 | 614 | 0.160 |
Why?
| | Massachusetts | 2 | 2017 | 159 | 0.160 |
Why?
| | Genome-Wide Association Study | 2 | 2025 | 1326 | 0.160 |
Why?
| | Echocardiography, Stress | 1 | 2019 | 20 | 0.160 |
Why?
| | Delivery of Health Care | 2 | 2023 | 900 | 0.160 |
Why?
| | Health Facilities | 1 | 2019 | 80 | 0.160 |
Why?
| | Fluid Therapy | 1 | 2020 | 133 | 0.160 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2019 | 58 | 0.160 |
Why?
| | Intraoperative Period | 1 | 2019 | 53 | 0.150 |
Why?
| | Socioeconomic Factors | 1 | 2023 | 1214 | 0.150 |
Why?
| | Vascular Resistance | 1 | 2020 | 371 | 0.150 |
Why?
| | Heart | 1 | 2022 | 645 | 0.150 |
Why?
| | Centralized Hospital Services | 1 | 2018 | 6 | 0.150 |
Why?
| | Thrombosis | 1 | 2022 | 349 | 0.150 |
Why?
| | Perioperative Care | 1 | 2020 | 150 | 0.150 |
Why?
| | Secondary Prevention | 1 | 2019 | 219 | 0.150 |
Why?
| | Colorado | 8 | 2019 | 4405 | 0.150 |
Why?
| | Perception | 1 | 2021 | 347 | 0.150 |
Why?
| | Biomarkers | 4 | 2017 | 3969 | 0.150 |
Why?
| | Angioplasty, Balloon, Laser-Assisted | 1 | 2017 | 1 | 0.150 |
Why?
| | Disease-Free Survival | 5 | 2017 | 646 | 0.150 |
Why?
| | Transportation of Patients | 1 | 2018 | 50 | 0.140 |
Why?
| | Angioplasty | 1 | 2018 | 47 | 0.140 |
Why?
| | Pregnancy-Associated Plasma Protein-A | 1 | 2017 | 14 | 0.140 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2023 | 2443 | 0.140 |
Why?
| | Cardiac Catheters | 1 | 2017 | 15 | 0.140 |
Why?
| | Algorithms | 2 | 2017 | 1616 | 0.140 |
Why?
| | Rosuvastatin Calcium | 1 | 2017 | 20 | 0.140 |
Why?
| | Clinical Competence | 1 | 2025 | 1018 | 0.140 |
Why?
| | ADAMTS13 Protein | 1 | 2017 | 6 | 0.140 |
Why?
| | Macrophage Colony-Stimulating Factor | 2 | 2008 | 17 | 0.140 |
Why?
| | Computer Simulation | 1 | 2021 | 940 | 0.140 |
Why?
| | Pulmonary Artery | 1 | 2023 | 1097 | 0.140 |
Why?
| | Neck | 1 | 2017 | 95 | 0.140 |
Why?
| | Thrombotic Microangiopathies | 1 | 2017 | 15 | 0.140 |
Why?
| | Ankle Brachial Index | 1 | 2017 | 36 | 0.130 |
Why?
| | Reproducibility of Results | 5 | 2025 | 3084 | 0.130 |
Why?
| | Risk | 2 | 2019 | 855 | 0.130 |
Why?
| | Suction | 2 | 2014 | 32 | 0.130 |
Why?
| | Adult | 7 | 2024 | 35607 | 0.130 |
Why?
| | Policy Making | 1 | 2017 | 88 | 0.130 |
Why?
| | Aortic Valve Stenosis | 1 | 2019 | 218 | 0.130 |
Why?
| | Cardiovascular Diseases | 2 | 2020 | 2008 | 0.130 |
Why?
| | Flow Cytometry | 2 | 2015 | 1160 | 0.130 |
Why?
| | Aortic Valve | 1 | 2019 | 347 | 0.130 |
Why?
| | Health Services Needs and Demand | 1 | 2018 | 263 | 0.130 |
Why?
| | Boston | 1 | 2016 | 89 | 0.130 |
Why?
| | Academic Medical Centers | 2 | 2016 | 481 | 0.130 |
Why?
| | Burnout, Professional | 1 | 2022 | 408 | 0.120 |
Why?
| | Dyslipidemias | 1 | 2017 | 177 | 0.120 |
Why?
| | Pandemics | 2 | 2021 | 1496 | 0.120 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2018 | 249 | 0.120 |
Why?
| | Cholesterol | 2 | 2008 | 412 | 0.120 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2007 | 216 | 0.120 |
Why?
| | Gene Expression Profiling | 2 | 2015 | 1686 | 0.120 |
Why?
| | Contraindications | 1 | 2014 | 90 | 0.120 |
Why?
| | Antithrombins | 1 | 2015 | 58 | 0.110 |
Why?
| | Aortic Diseases | 1 | 2016 | 113 | 0.110 |
Why?
| | Collateral Circulation | 1 | 2014 | 18 | 0.110 |
Why?
| | Models, Cardiovascular | 1 | 2015 | 192 | 0.110 |
Why?
| | Prevalence | 2 | 2019 | 2563 | 0.110 |
Why?
| | Prospective Studies | 3 | 2020 | 7145 | 0.110 |
Why?
| | Observer Variation | 3 | 2025 | 314 | 0.110 |
Why?
| | Heparin | 1 | 2015 | 254 | 0.100 |
Why?
| | Resuscitation | 1 | 2015 | 237 | 0.100 |
Why?
| | Diabetes Mellitus | 2 | 2018 | 1003 | 0.100 |
Why?
| | Incidental Findings | 1 | 2013 | 80 | 0.100 |
Why?
| | Primary Prevention | 1 | 2014 | 190 | 0.100 |
Why?
| | Smoking Cessation | 1 | 2016 | 409 | 0.100 |
Why?
| | Electronic Health Records | 2 | 2017 | 975 | 0.090 |
Why?
| | Coronary Disease | 1 | 2014 | 385 | 0.090 |
Why?
| | Trazodone | 1 | 2011 | 2 | 0.090 |
Why?
| | Antimanic Agents | 1 | 2011 | 18 | 0.090 |
Why?
| | Lithium | 1 | 2011 | 37 | 0.090 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 2 | 2023 | 92 | 0.090 |
Why?
| | Triazines | 1 | 2011 | 38 | 0.090 |
Why?
| | Health Services Accessibility | 1 | 2018 | 903 | 0.090 |
Why?
| | Laboratories | 2 | 2022 | 109 | 0.090 |
Why?
| | American Heart Association | 2 | 2022 | 300 | 0.090 |
Why?
| | Prosthesis Design | 3 | 2017 | 309 | 0.090 |
Why?
| | Decision Support Techniques | 1 | 2014 | 398 | 0.090 |
Why?
| | Benzodiazepines | 1 | 2011 | 137 | 0.090 |
Why?
| | Anticonvulsants | 1 | 2011 | 208 | 0.080 |
Why?
| | Cell Differentiation | 2 | 2008 | 1900 | 0.080 |
Why?
| | Age Factors | 4 | 2019 | 3153 | 0.080 |
Why?
| | Lipoproteins, LDL | 2 | 2007 | 127 | 0.080 |
Why?
| | Depression | 1 | 2018 | 1322 | 0.080 |
Why?
| | Bipolar Disorder | 1 | 2011 | 236 | 0.080 |
Why?
| | MicroRNAs | 1 | 2015 | 680 | 0.070 |
Why?
| | Seizures | 1 | 2011 | 401 | 0.070 |
Why?
| | Animals | 4 | 2025 | 35404 | 0.070 |
Why?
| | Pinocytosis | 1 | 2007 | 10 | 0.070 |
Why?
| | Area Under Curve | 1 | 2008 | 306 | 0.070 |
Why?
| | Ultrasonography, Doppler, Duplex | 2 | 2017 | 43 | 0.070 |
Why?
| | Monocytes | 2 | 2007 | 553 | 0.070 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 147 | 0.070 |
Why?
| | Fluorescent Antibody Technique | 1 | 2008 | 377 | 0.070 |
Why?
| | Drug Overdose | 1 | 2011 | 325 | 0.070 |
Why?
| | Phenotype | 2 | 2021 | 3062 | 0.070 |
Why?
| | ROC Curve | 1 | 2008 | 503 | 0.060 |
Why?
| | Inflammation | 3 | 2008 | 2748 | 0.060 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2019 | 321 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2025 | 2062 | 0.060 |
Why?
| | Shock | 2 | 2004 | 92 | 0.060 |
Why?
| | Equipment Design | 2 | 2018 | 514 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1033 | 0.060 |
Why?
| | Exercise | 1 | 2016 | 1933 | 0.060 |
Why?
| | Program Evaluation | 2 | 2019 | 877 | 0.060 |
Why?
| | Lipid Metabolism | 1 | 2008 | 503 | 0.060 |
Why?
| | Survival Analysis | 2 | 2020 | 1270 | 0.060 |
Why?
| | Ventricular Fibrillation | 1 | 2024 | 57 | 0.060 |
Why?
| | Trypsin | 1 | 2004 | 74 | 0.060 |
Why?
| | Length of Stay | 2 | 2019 | 1127 | 0.050 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2004 | 124 | 0.050 |
Why?
| | Amylases | 1 | 2003 | 17 | 0.050 |
Why?
| | Chymotrypsin | 1 | 2003 | 19 | 0.050 |
Why?
| | Ezetimibe | 1 | 2023 | 25 | 0.050 |
Why?
| | Hypoglycemic Agents | 2 | 2023 | 1220 | 0.050 |
Why?
| | Tissue Distribution | 1 | 2003 | 316 | 0.050 |
Why?
| | Tachycardia, Ventricular | 1 | 2024 | 168 | 0.050 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2023 | 114 | 0.050 |
Why?
| | Drug Therapy, Combination | 2 | 2016 | 1042 | 0.050 |
Why?
| | Pancreatitis | 1 | 2003 | 129 | 0.050 |
Why?
| | Rats, Wistar | 1 | 2003 | 443 | 0.050 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1506 | 0.050 |
Why?
| | Personnel Turnover | 1 | 2022 | 39 | 0.050 |
Why?
| | Liver Cirrhosis | 1 | 2024 | 281 | 0.050 |
Why?
| | Cell Death | 1 | 2003 | 352 | 0.050 |
Why?
| | Reperfusion Injury | 1 | 2004 | 272 | 0.050 |
Why?
| | Cholesterol, LDL | 1 | 2023 | 358 | 0.050 |
Why?
| | Ambulatory Care | 1 | 2025 | 506 | 0.040 |
Why?
| | Neutrophils | 2 | 2004 | 1209 | 0.040 |
Why?
| | Troponin | 1 | 2021 | 50 | 0.040 |
Why?
| | Disease Progression | 2 | 2019 | 2628 | 0.040 |
Why?
| | Organizational Culture | 1 | 2022 | 139 | 0.040 |
Why?
| | Inpatients | 1 | 2025 | 477 | 0.040 |
Why?
| | Systole | 1 | 2021 | 191 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2008 | 4102 | 0.040 |
Why?
| | Sodium Bicarbonate | 1 | 2020 | 37 | 0.040 |
Why?
| | Free Radical Scavengers | 1 | 2020 | 83 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2007 | 1441 | 0.040 |
Why?
| | Job Satisfaction | 1 | 2022 | 202 | 0.040 |
Why?
| | Cytokines | 1 | 2008 | 2022 | 0.040 |
Why?
| | Consensus | 1 | 2023 | 617 | 0.040 |
Why?
| | Sodium | 1 | 2020 | 205 | 0.040 |
Why?
| | Hospitals, High-Volume | 1 | 2019 | 39 | 0.040 |
Why?
| | Acetylcysteine | 1 | 2020 | 146 | 0.040 |
Why?
| | Exercise Tolerance | 1 | 2021 | 273 | 0.040 |
Why?
| | Cost Savings | 1 | 2019 | 78 | 0.040 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2019 | 89 | 0.040 |
Why?
| | Endocrinologists | 1 | 2018 | 12 | 0.040 |
Why?
| | Retreatment | 1 | 2018 | 70 | 0.040 |
Why?
| | Drug Utilization | 1 | 2019 | 171 | 0.040 |
Why?
| | Comparative Effectiveness Research | 1 | 2019 | 151 | 0.040 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2019 | 198 | 0.040 |
Why?
| | Hypertension | 2 | 2018 | 1242 | 0.040 |
Why?
| | Rats | 2 | 2004 | 5485 | 0.040 |
Why?
| | Transcription Factors | 1 | 2006 | 1645 | 0.040 |
Why?
| | Republic of Korea | 1 | 2017 | 29 | 0.040 |
Why?
| | Singapore | 1 | 2017 | 20 | 0.040 |
Why?
| | Angina, Unstable | 1 | 2017 | 76 | 0.030 |
Why?
| | Purpura, Thrombotic Thrombocytopenic | 1 | 2017 | 12 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1201 | 0.030 |
Why?
| | New Jersey | 1 | 2016 | 12 | 0.030 |
Why?
| | Michigan | 1 | 2016 | 104 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2020 | 711 | 0.030 |
Why?
| | Aortography | 1 | 2016 | 51 | 0.030 |
Why?
| | Postoperative Care | 1 | 2017 | 239 | 0.030 |
Why?
| | Platelet Aggregation | 1 | 2016 | 97 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2019 | 527 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2017 | 248 | 0.030 |
Why?
| | Glucose | 1 | 2020 | 1003 | 0.030 |
Why?
| | Blood Transfusion | 1 | 2017 | 295 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 821 | 0.030 |
Why?
| | Hirudins | 1 | 2015 | 53 | 0.030 |
Why?
| | Blood Coagulation | 1 | 2016 | 239 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 1005 | 0.030 |
Why?
| | Protective Factors | 1 | 2014 | 91 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2271 | 0.030 |
Why?
| | Lipids | 1 | 2017 | 628 | 0.030 |
Why?
| | Health Policy | 1 | 2016 | 354 | 0.030 |
Why?
| | Emergencies | 1 | 2013 | 156 | 0.020 |
Why?
| | Blood Flow Velocity | 1 | 2014 | 406 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2015 | 1310 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 569 | 0.020 |
Why?
| | Health Care Costs | 1 | 2014 | 367 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 2017 | 546 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2724 | 0.020 |
Why?
| | Models, Biological | 1 | 2017 | 1724 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 5427 | 0.020 |
Why?
| | Medicare | 1 | 2014 | 719 | 0.020 |
Why?
| | Mice | 1 | 2025 | 16982 | 0.020 |
Why?
| | Clofibrate | 1 | 2007 | 4 | 0.020 |
Why?
| | Orphan Nuclear Receptors | 1 | 2007 | 15 | 0.020 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 1 | 2007 | 15 | 0.020 |
Why?
| | Hydrocarbons, Fluorinated | 1 | 2007 | 9 | 0.020 |
Why?
| | Liver X Receptors | 1 | 2007 | 31 | 0.020 |
Why?
| | beta-Cyclodextrins | 1 | 2007 | 27 | 0.020 |
Why?
| | Down-Regulation | 1 | 2007 | 631 | 0.010 |
Why?
| | Physicians | 1 | 2013 | 871 | 0.010 |
Why?
| | Telemedicine | 1 | 2013 | 792 | 0.010 |
Why?
| | Mesenteric Arteries | 1 | 2004 | 17 | 0.010 |
Why?
| | Jejunum | 1 | 2004 | 30 | 0.010 |
Why?
| | Gelatin | 1 | 2004 | 42 | 0.010 |
Why?
| | Interleukin-10 | 1 | 2006 | 304 | 0.010 |
Why?
| | Peroxidase | 1 | 2004 | 175 | 0.010 |
Why?
| | Sulfonamides | 1 | 2007 | 497 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 2004 | 399 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2004 | 812 | 0.010 |
Why?
| | Blotting, Western | 1 | 2004 | 1204 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2004 | 2403 | 0.010 |
Why?
|
|
Waldo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|